Understanding TreatmentOptions in
Cutaneous Lymphoma
Clinical Trials
28
29
4
(Adcetris®), an immunoconjugate (monoclonal antibodywith a chemotherapy
drug attached) that targets amarker on the surface ofT-cell andB-cell tumors.
Once brentuximab vedotin enters cells, it releases a chemotherapy agent to
destroy the cell.
As clinical trials reveal what agents are effective in the treatment of cutaneous
lymphoma, new agents are being developed and studied in classes of drugs
that have shownpromise.Novel histone deacetylase (HDAC) inhibitors such
as quisinostat (JNJ-26481585) for the treatment ofCTCL and a novel pan-
deacetylase inhibitor, panobinostat (LBH589), for treatment ofCTCLs are
undergoing clinical trials.
As researchers learnmore about how cancer cellswork, other classes of novel
agents that target specific tumor cell signaling, transduction, proliferation,
and survival pathways, such as agents that target phosphoinositide 3-kinase
(PI3K) andmammalian target of rapamycin (mTOR), are also being developed
and evaluated inpreclinical and clinical trials. Ibrutinib (PCI-32765), an
oral Bruton’s tyrosine kinase inhibitor for treatment of B-cellmalignancies,
including cutaneous B-cell lymphoma, is being tested in clinical trials.
Formore details on active clinical trials inCTCL, please visit theCutaneous
LymphomaFoundation’swebsite at
.
